Related Experiment Video
Updated: May 6, 2026
Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
Treatment of Guillain-Barré syndrome
1UCLA Health System, Los Angeles, California. Norma D. McNair, PhD, RN, CNRN, is the interim director of research and evidence-based practice for the UCLA Health System. She was formerly a clinical nurse specialist at Ronald Reagan UCLA Medical Center in Los Angeles, California.
Abstract:
Guillain-Barré syndrome (GBS) is an idiopathic postinfectious immune disease that leads to progressive motor weakness due to damage to the myelin sheath. Epidemiological studies have linked GBS to infections from Campylobacter jejuni, Cytomegalovirus, and other pathogens. The syndrome includes multiple subtypes, with the most common being ascending motor weakness. Treatment with intravenous immunoglobulin and plasma exchange reduces the time for recovery to occur, although some remain disabled.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:19Depolarizing Blockers: Pharmocokinetics